<DOC>
	<DOCNO>NCT00079313</DOCNO>
	<brief_summary>This study evaluate safety effectiveness imatinib ( Gleevec ( Registered Trademark ) ) patient chronic myelomonocytic leukemia ( CMML ) atypical chronic myelogenous leukemia ( CML ) . These condition cause uncontrolled growth malignant ( cancerous ) cell bone marrow prevents bone marrow function normally produce blood cell . The cancer cell also spill blood invade organ body . Imatinib approve Food Drug Administration treat chronic myelogenous leukemia , characteristic similar atypical CML CMML , data research suggest drug may able produce remission form leukemia CML . Patients 18 year age atypical CML CMML may eligible study . Candidates screen medical history physical examination , blood test , electrocardiogram , chest x-ray , bone marrow aspiration biopsy ( removal small piece bone marrow tissue needle insert hip bone ) . Participants take imatinib capsule day 2 year . If time study patient 's blood count begin rise , disease symptom develop , disease progress , dose imatinib increase week disease progression stop . Any patient whose disease response treatment 6 week increase dose 30 day maximum daily dose 800 mg take study refer different treatment . Patients see refer physician every week first 4 week study , every week next 8 week , monthly study complete . At visit , blood drawn monitor drug side effect response therapy . In addition , patient come NIH Clinical Center every 3 month complete history physical examination bone marrow aspiration biopsy every 6 month assess effect treatment bone marrow cell . Patients leave study 2 year follow laboratory monitoring 6 month stop imatinib ; remain drug full 2 year monitor 1 year stop drug .</brief_summary>
	<brief_title>Imatinib ( Gleevec ( Registered Trademark ) ) Treat Chronic Myelomonocytic Leukemia Atypical Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>The purpose study evaluate safety effectiveness imatinib improve blood count patient chronic myelomonocytic leukemia ( CMML ) atypical chronic myelogenous leukemia ( CML ) . Although number agent use treat disease , patient respond treatment . Imatinib show clinical trial induce high rate response patient chronic phase CML . Imatinib also show effective inducing response subset patient CMML atypical CML also effective subset patient idiopathic hypereosinophilic syndrome ( HES ) , another myeloproliferative disorder . Because patient several different myeloproliferative disease show experience dramatic response imatinib , would like determine proportion patient atypical myeloproliferative disease ( CMML atypical CML ) respond agent . Prior enrollment , thorough clinical evaluation perform . A baseline bone marrow obtain exclude acute leukemia lymphoma ass degree nature myeloproliferation . In order minimize bone marrow suppression , myelosuppressive drug taper discontinue first week therapy imatinib . Complete blood count perform weekly first month every week thereafter . Clinical assessment perform every three month assess continue response .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>INCLUSION CRITERIA : All subject must great equal 18 year age . All subject must meet establish diagnostic criterion CMML atypical CML . The diagnostic criterion CMML include : persistent peripheral blood monocytosis ( great 1000/mm ( 3 ) ) , Philadelphia chromosome BCR/ABL fusion gene , few 20 % blast blood bone marrow , dysplasia one myeloid lineages . If dysplasia absent diagnosis CMML still make requirement meet cytogenetic abnormality present marrow cell monocytosis persistent least 3 month cause monocytosis exclude . OR The diagnostic criterion atypical CML include : peripheral blood leukocytosis comprise increased mature immature neutrophil , prominent dysgranulopoiesis , Philadelphia chromosome BCR/ABL fusion gene , neutrophil precursor great equal 10 % white blood cell , basophils less 2 % white blood cell , monocytes less 10 % white blood cell , hypercellular bone marrow granulocytic proliferation dysplasia , few 20 % blast blood bone marrow . Serum creatinine le 2mg/dl ECOG performance status le 3 Life expectancy great 12 week All subject ( men woman ) must agree practice abstinence effective contraception administration imatinib . Patients must able comprehend investigational nature research willing sign inform consent . EXCLUSION CRITERIA : Pregnancy lactation . HIV positivity know immunodeficiency . Absolute neutrophil count le 1000/mm ( 3 ) platelet count le 10,000/mm ( 3 ) less 50,000/m ( 3 ) clinical evidence bleeding . Infection adequately respond appropriate therapy History nonhematologic malignancy treat chemotherapy past 5 year . A moribund status concurrent hepatic , renal , cardiac , metabolic disease severity death within 12 week initiation therapy likely . Treatment investigational agent ( hematopoietic growth factor ) within 4 week study entry . Psychiatric , affective , disorder may compromise ability give informed consent cooperate research study . Elevated transaminase ( great 5 time upper limit normal ) elevate bilirubin ( great 3 time upper limit normal ) . Recent exposure chickenpox recent history Herpes zoster ( shingle ) reactivation . Imatinib may put patient increase risk severe disease . Left ventricular ejection fraction le 45 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 23, 2011</verification_date>
	<keyword>CMML</keyword>
	<keyword>CML</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Glivec</keyword>
	<keyword>STI-571</keyword>
	<keyword>Tyrosine Kinase Inhibitor</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Atypical Chronic Myelogenous Leukemia</keyword>
	<keyword>Chronic Myelomoncytic Leukemia</keyword>
	<keyword>Leukemia</keyword>
</DOC>